Mallinckrodt, the Pharmaceuticals business of Covidien COV, today
announced that it has entered into an agreement with Xanodyne Pharmaceuticals
to purchase Roxicodone^® (oxycodone hydrochloride tablets USP) in 5, 15 and 30
mg dosage strengths. Roxicodone, currently marketed in the United States, is
an immediate release formulation of oxycodone indicated for the management of
moderate to severe pain where the use of an opioid analgesic is appropriate.
With this agreement, Mallinckrodt acquires all rights to the Roxicodone New
Drug Application (NDA). No financial details were disclosed.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in